US Patent

US9399775 — RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2032-11-16 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects RNAi agents that target the transthyretin (TTR) gene and methods of using them to treat or prevent TTR-associated diseases.

USPTO Abstract

The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3396`	—	vutrisiran-sodium

Patent Metadata

Patent number: US9399775
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-16
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.